Drug Profile

Research programme: tetracosactide - Travere Therapeutics

Alternative Names: 1-24-Corticotropin - Travere Therapeutics; ACTH (1-24) - Travere Therapeutics; Cosyntropin - Travere Therapeutics; RE-034

Latest Information Update: 24 Nov 2020

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Retrophin
Developer Travere Therapeutics
Class Anti-inflammatories; Antidepressants; Corticosteroids; Diagnostic agents; Immunotherapies; Melanocortins; Peptides
Mechanism of Action Melanocortin receptor agonists; Steroid receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

16 Nov 2020 Retrophin is now called Travere Therapeutics
28 Jul 2018 No recent reports of development identified for preclinical development in Infantile spasms in USA (Parenteral)
28 Jul 2018 No recent reports of development identified for preclinical development in Nephrotic-syndrome in USA (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com